Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

BACKGROUND/AIMS: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to tha...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Mol Hepatol
Hoofdauteurs: Jeon, Mi Young, Kim, Beom Kyung, Lee, Jae Seung, Lee, Hye Won, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Kim, Seung Up
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: The Korean Association for the Study of the Liver 2021
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046628/
https://ncbi.nlm.nih.gov/pubmed/33317247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2020.0216
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items